Antihypertensive Therapeutics Market Size, Share, Growth & Analysis Report 2020: Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, ''Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'', which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. Browse Full Report With TOC @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.
GBI Research, the leading business intelligence provider, has released its latest research, ''Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'', which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
Browse Full Report With TOC @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries
The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Reasons to buy<br />
The report will enhance your decision-making capability by allowing you to -<br />
- Align your product portfolio to the markets with high growth potential<br />
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic<br />
segments poised for strong growth<br />
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers<br />
in the hypertension therapeutics market<br />
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies<br />
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions<br />
and strategic partnerships<br />
Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/antihypertensivetherapeutics-in-major-developed-markets-to-<strong>2020</strong>-increased-uptake-of-combination-therapies-tooffset-effects-of-key-patent-expiries<br />
Table of Contents<br />
Table of Contents 4<br />
1.1 List of Tables 6<br />
1.2 List of Figures 7<br />
2 Introduction 8<br />
2.1 Pathophysiology 8<br />
2.2 Etiology 9<br />
2.3 Signs and Symptoms 9<br />
2.4 Co-Morbidities and Complications 10<br />
2.5 Diagnosis 11<br />
2.5.1 Office Blood Pressure Monitoring 11<br />
2.5.2 Ambulatory Blood Pressure Monitoring 11<br />
2.5.3 Home Blood Pressure Monitoring 11<br />
2.5.4 Miscellaneous Methods 11
Change language